Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02513264 · ClinicalTrials.gov registry record
Registry for Asthma Characterization and Recruitment 2
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 1,384
- Enrollment target
NCT02513264: Completed study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT02513264 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 1,384 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02513264 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 1,384 participants
- Enrollment target
Study Summary
There is a need for people to take part in research studies to learn more about diseases and how to treat them. The Registry for Asthma Characterization and Recruitment 2 (RACR2) will create a database of participants with asthma and nasal allergies, or risk factors for these conditions, who are potentially eligible for future Inner City Asthma Consortium (ICAC) trials. The registry database will include assessments of various asthma and allergy characteristics to achieve a more efficient, selective recruitment of these participants for other protocols.
Primary Outcome
Characteristics of the participants enrolled in the registry will be assessed on a periodic basis (descriptive summary of diagnosis and parameters associated with the former).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,384 participants |
| Start Date | 2015-04-14 |
| Est. Completion | 2020-03-13 |
What the finished NCT02513264 record still lists
NCT02513264 is an observational study that tracks outcomes without assigning an intervention. Its 1,384 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT02513264 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02513264 about?
NCT02513264 is a clinical study titled "Registry for Asthma Characterization and Recruitment 2". There is a need for people to take part in research studies to learn more about diseases and how to treat them. The Registry for Asthma Characterization and Recruitment 2 (RACR2) will create a database of participants with asthma and nasal allergies, or risk factors for these conditions, who are pot...
What is the current status of trial NCT02513264?
This trial is currently completed. The enrollment target is 1,384 participants. The study started on 2015-04-14. Estimated completion is 2020-03-13.
Who is sponsoring clinical trial NCT02513264?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06651281 · 1,380 participants · Phase 3
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- NCT05006131 · 1,395 participants
Pancreatic Cancer Screening for At-risk Individuals
- NCT07256392 · 1,370 participants · Phase 3
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
- NCT02205762 · 1,400 participants · Phase 2
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI